Bvf Inc Immunovant, Inc. Transaction History

Bvf Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $5.57 Million - $12 Million	300,000 New	300,000 $11.5 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $16.9 Million - $45.5 Million	2,561,000 New	2,561,000 $45.5 Million
Q3 2021 Nov 15, 2021	SELL	$7.01 - $11.37 $8.93 Million - $14.5 Million	-1,273,516 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $1.22 Million - $2.18 Million	129,500 Added 11.32%	1,273,516 $13.5 Million
Q1 2021 May 17, 2021	BUY	$13.08 - $49.6 $8.24 Million - $31.2 Million	629,646 Added 122.41%	1,144,016 $18.4 Million
Q4 2020 Feb 12, 2021	SELL	$36.36 - $52.71 $24.9 Million - $36.1 Million	-684,057 Reduced 57.08%	514,370 $23.8 Million
Q3 2020 Nov 13, 2020	BUY	$22.61 - $38.9 $2.49 Million - $4.28 Million	109,948 Added 10.1%	1,198,427 $42.2 Million
Q2 2020 Aug 14, 2020	BUY	$13.87 - $28.44 $1.23 Million - $2.52 Million	88,483 Added 8.85%	1,088,479 $26.5 Million
Q4 2019 Feb 14, 2020	BUY	$10.02 - $16.4 $10 Million - $16.4 Million	999,996 New	999,996 $15.9 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.